Clinical trial
A Randomized Open Label Phase II Trial of Aprepitant (Emend) in Combination With Ondansetron Compared to Standard 5HT3 Serotonin Antagonist (Ondansetron) in the Prevention of Acute and Delayed Chemotherapy Induced Nausea and Vomiting (CINV) in Glioma Patients Receiving a Temozolomide Based Regimen
NCT01450826 is registered in ClinicalTrials.gov with Katy Peters as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- A Randomized Open Label Phase II Trial of Aprepitant (Emend) in Combination With Ondansetron Compared to Standard 5HT3 Serotonin Antagonist (Ondansetron) in the Prevention of Acute and Delayed Chemotherapy Induced Nausea and Vomiting (CINV) in Glioma Patients Receiving a Temozolomide Based Regimen
- Lead sponsor
- Katy Peters
- Phase
- Phase 2
- Overall status
- Completed
- Start date
- June 24, 2014
- Completion date
- April 21, 2017
- Enrollment
- 136 (actual)
- Sites
- 1
Conditions
As the registry lists them; a condition with its own page is linked.